ATE190502T1 - Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken - Google Patents

Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken

Info

Publication number
ATE190502T1
ATE190502T1 AT94106827T AT94106827T ATE190502T1 AT E190502 T1 ATE190502 T1 AT E190502T1 AT 94106827 T AT94106827 T AT 94106827T AT 94106827 T AT94106827 T AT 94106827T AT E190502 T1 ATE190502 T1 AT E190502T1
Authority
AT
Austria
Prior art keywords
gram
membrane proteins
outer membrane
lot
preparation
Prior art date
Application number
AT94106827T
Other languages
English (en)
Inventor
Gary W Zlotnick
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE190502T1 publication Critical patent/ATE190502T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
AT94106827T 1993-05-13 1994-05-02 Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken ATE190502T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6158193A 1993-05-13 1993-05-13

Publications (1)

Publication Number Publication Date
ATE190502T1 true ATE190502T1 (de) 2000-04-15

Family

ID=22036711

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94106827T ATE190502T1 (de) 1993-05-13 1994-05-02 Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken

Country Status (11)

Country Link
US (2) US6355253B1 (de)
EP (1) EP0624376B1 (de)
JP (1) JP3711289B2 (de)
KR (1) KR100355961B1 (de)
AT (1) ATE190502T1 (de)
CA (1) CA2123355C (de)
DE (1) DE69423383T2 (de)
DK (1) DK0624376T3 (de)
ES (1) ES2145072T3 (de)
GR (1) GR3033469T3 (de)
PT (1) PT624376E (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121427A (en) * 1994-10-24 2000-09-19 Connaught Laboratories Limited Major outer membrane protein CD of branhamella
US20040087020A1 (en) 1997-05-28 2004-05-06 Chiron S.P.A. Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
EP2199382A3 (de) * 1997-05-28 2010-09-22 Novartis Vaccines and Diagnostics S.r.l. Kulturmedium mit Hefe- oder Sojabohnenextrakt als Aminosäurenquelle und ohne Proteinkomplexe tierischer Herkunft
ES2301181T3 (es) * 1997-08-21 2008-06-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas.
EP2261345A3 (de) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
AU761495B2 (en) 1998-05-29 2003-06-05 Chiron Corporation Combination meningitidis B/C vaccines
DK2270173T3 (en) 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT1248647E (pt) * 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
WO2004052281A2 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7608278B2 (en) 2003-12-30 2009-10-27 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2006089264A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
KR100612895B1 (ko) * 2005-05-04 2006-08-14 삼성전자주식회사 화학 물질을 이용한 생물학적 시료로부터 단백질의선택적인 제거 방법
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
RU2477145C2 (ru) * 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
DK3246044T3 (da) 2010-08-23 2021-01-18 Wyeth Llc Stabile formuleringer af Neisseria-meningitidis-RLP2086-antigener
EP3549601B1 (de) 2010-09-10 2021-02-24 Wyeth LLC Non-lipidierten varianten von neisseria meningitidis orf2086 antigene
WO2012032498A2 (en) * 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
SG10201602558UA (en) 2012-03-09 2016-05-30 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
RU2662970C2 (ru) 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
JP6546654B2 (ja) 2014-08-22 2019-07-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 淋菌感染を治療するための三環式含窒素化合物
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
BR112019014397A2 (pt) 2017-01-31 2020-02-11 Pfizer Inc. Composições de neisseria meningitidis e métodos das mesmas
CN110568116A (zh) * 2019-09-17 2019-12-13 广东医科大学附属医院 一种筛选用于诊断阿尔茨海默病的生物标志物的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4386066A (en) * 1981-08-20 1983-05-31 Merck & Co., Inc. Immunogenic complex from N. gonorrhoeae
WO1983003354A1 (en) 1982-03-30 1983-10-13 Us Army Neisseria gonorrhoeae vaccine
NL8403195A (nl) 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
DE3516017A1 (de) 1985-05-02 1986-11-27 Jochen 1000 Berlin Kittel Verfahren zur herstellung membranstaendiger proteine aus biologischem material zur anwendung im biologischen systemen
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в
CA1338708C (en) * 1988-06-29 1996-11-12 Lee Mark Wetzler Neisserial vaccines
ATE120093T1 (de) 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
CA2047681C (en) * 1989-03-09 2000-02-01 Bruce A. Green Vaccines for nontypable haemophilus influenzae
ATE108557T1 (de) 1989-04-14 1994-07-15 Unilever Nv Extraktionsverfahren.
US5552146A (en) * 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis

Also Published As

Publication number Publication date
JPH0819396A (ja) 1996-01-23
DK0624376T3 (da) 2000-07-24
PT624376E (pt) 2000-07-31
DE69423383T2 (de) 2000-08-24
DE69423383D1 (de) 2000-04-20
US6355253B1 (en) 2002-03-12
EP0624376A1 (de) 1994-11-17
CA2123355C (en) 2007-08-28
US6921537B2 (en) 2005-07-26
KR100355961B1 (ko) 2002-12-26
GR3033469T3 (en) 2000-09-29
US20020136741A1 (en) 2002-09-26
ES2145072T3 (es) 2000-07-01
JP3711289B2 (ja) 2005-11-02
CA2123355A1 (en) 1994-11-14
EP0624376B1 (de) 2000-03-15

Similar Documents

Publication Publication Date Title
ATE190502T1 (de) Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken
NO913518L (no) Vaksiner for ikke typebestembar haemophilus influenzae.
DE68921895T3 (de) Meningococcales klasse i-aussenmembranprotein-vakzin.
SI2351579T1 (sl) Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
ES485715A1 (es) Procedimiento mejorado para la preparacion de proteinas de membranas
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
NO931093L (no) Fremgangsmaate for fremstilling av rensede glykolipider ved membrana dskillelsesfremgangsmaaten
EP0761230A2 (de) Aus Bordetella pertussis Aussenmembranprotein enthaltender Impfstoffe und Verfahren zu seiner Herstellung
WO1998011229A3 (en) Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
ATE130198T1 (de) Herstellung eines virus und reinigung von virenüberzugsproteinen zur impfstoffverwendung.
DE3884680D1 (de) Äusseres Membranprotein F von Pseudomonas aeruginosa.
DK398683A (da) Fremgangsmaade til fremstilling af antistoffer
NO951750L (no) Renset "nontypable" Haemophilus influenzae P5 protein som en vaksine for "nontypable" Haemophilus influenzae stamme
FI102544B1 (fi) Menetelmä E.coli-kannan valmistamiseksi
Rappaport et al. Development of a purified cholera toxoid. III. Refinements in purification of toxin and methods for the determination of residual somatic antigen
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
FR2517967B1 (de)
NO912822L (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
Novotny Effect of Growth Conditions on the Composition and Stability of the Outer Membrane of Bordetella pertussis P. Novotny and K. Cownley
NO912824D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet frayttermembranen til neisseria meningitidis.
PT92807A (pt) Processo para a preparacao de uma vacina de proteina de membrana externa meningococia classe 1
ES2103818T3 (es) Procedimiento para la preparacion de 17-oxo-esteroides.
WO2001044278A3 (en) Antigen preparations
NO911049L (no) Matrise med immun-modulerende aktivitet.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee